We currently have the following ongoing clinical trials:

Phase 2b trial in unipolar depression (RAPID)

The RAPID trial is a double-blind, randomized, sham-controlled phase 2 study of LFMS augmentation of anti-depressant therapy in treatment resistant major depressive disorder. Using an innovative Sequential Parallel Comparison Design, the study tests 20 min LFMS treatment sessions over 2 and 4 consecutive days vs. sham in 90 patients, and measures the effect durability for one month. Six leading US research centers are participating in the study, with Massachusetts General Hospital being the lead site. The National Institute of Mental Health is fully funding the trial under its RAPID program.

For more information, please click here: https://clinicaltrials.gov/ct2/show/NCT01654796?term=lfms&rank=3

Weill Cornell Imaging study

The Weill Cornell Imaging study is a double-blind, randomized, sham-controlled phase 2 study of LFMS effects on brain circuitry of adults with treatment-resistant major depressive disorder. Using three distinct MRI techniques, the study goal is to help us better understand the physiological effects and mechanism of action of LFMS.

For more information, please click here: https://clinicaltrials.gov/ct2/show/NCT01944644?term=lfms&rank=